null - FindTrial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-000526-21-SE

Enrollment

Registered

2012-03-12

Start date

2012-05-07

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: HLT Classification code 10028229 Term: Multiple myelomas System Organ Class: 10005329 - Blood and lymphatic system disorders

Interventions

Trade Name: Prevenar 13, Injektionsvätska, suspension Pharmaceutical Form: Suspension for injection Trade Name: Pneumovax® Injektionsvätska, lösning Pharmaceutical Form: Suspension for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 2

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Sweden

Contacts

Public ContactHematologen

Västra Götalandsregionen (VGR)

veronica.karlsson@vgregion.se460522939042138

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026